GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
OCS-01 failed to meet the primary endpoint of improving visual acuity in both Phase 3 DIAMOND studies. ・The treatment reduced ...
A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Health officials have issued a warning to weight loss jab users after a rare eye condition was linked to a popular medication ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults prescribed semaglutide were more likely to ...
Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic ...
USA, February 24, 2023 /EINPresswire.com/ -- NAION or Non-arteritic Ischemic Optic Neuropathy is a type of stroke of the optic nerve that is not from inflammation. It ...
Please provide your email address to receive an email when new articles are posted on . A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection ...
The study does not say that Wegovy directly causes blindness. Instead, researchers found a strong link between the drug and a ...
GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results